New: NCI-funded clinical trial search
Mednet Logo
CommunityHematology

Hematology

Clinical discussions on blood disorders, coagulation, transfusion medicine, and hematologic malignancies.

Recent Discussions

If a pregnant patient with a mechanical heart valve takes warfarin throughout her pregnancy, what are the chances that the fetus will be harmed?

1 Answers

Mednet MemberInvited Expert
Cardiology · University of Southern California

Warfarin is effective for thromboembolic prevention in pregnant patients with mechanical valves. There is however an overwhelming evidence that warfarin taken during pregnancy is deleterious to the fetus. Its use during the first 6–12 weeks of gestation can be associated with important fetal complic...

Would you recommend ISRT for an initially bulky nodular lymphocyte predominant Hodgkin lymphoma with complete metabolic response after 4 cycles of R-CHOP?

3 Answers

Mednet MemberInvited Expert
Radiation Oncology · Duke University Medical Center

Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare subtype of Hodgkin lymphoma. Approximately 95% of Hodgkin lymphoma cases are classified as classic Hodgkin lymphoma, including the nodular sclerosis, mixed cellularity, lymphocyte-rich, and lymphocyte-depleted subtypes, all of which a...

Do you do prophylactic LP/IT chemotherapy in high risk APML prior to starting consolidation?

1 Answers

Mednet MemberInvited Expert
Medical Oncology · Northwestern University

Extramedullary disease such as CNS involvement is quite uncommon at diagnosis in acute promyelocytic leukemia (APL). However, it can be seen in patients with relapsed disease. Both isolated CNS relapse and CNS relapse associated with morphologic or molecular relapse can occur. Yet one has the impres...

About Mednet

A community where doctors find answers to medicine's toughest questions.

  • Verified, credentialed physicians
  • 45,000+ members across 24 specialties
  • Free CME and MOC credit

What dose of radiotherapy do you use for low volume Castleman's disease?

1 Answers

Mednet Member
Radiation Oncology · MD Anderson Cancer Center

Reports in the literature are varied in terms of radiation dose. For scenarios such as this with low volume disease, it is probably reasonable to consider the lower end of ranges reported by others to be successful, such as 30 Gy. Careful pathology review is important for these cases as well. One mu...

Do you check IGHV mutation status in patients with newly diagnosed CLL?

1 Answers

Mednet Member
Medical Oncology · University of Kansas Cancer Center

Yes. In the targeted therapy era, there are three factors that continue to have prognostic and therapeutic significance and should be checked: IgHV mutation status p53 aberrancy - requires both FISH for del17p AND mutation analysis for p53 Complex karyotype - can be done on peripheral blood or marr...

Would you radiate the thoracic duct for bilateral chylothorax in a hematologic malignancy with no discrete adenopathy?

1
1 Answers

Mednet MemberInvited Expert
Radiation Oncology · Varian Medical Systems/Allegheny health network

We have done for adenopathy, which relieves obstruction and thus helps with drainage, but we don’t know how it would help in this situation.

Do you check LDH levels for patients with CLL who are asymptomatic and on surveillance?

1
1 Answers

Mednet MemberInvited Expert
Medical Oncology · UPMC Hillman Cancer Center

I personally include LDH as part of my routine chemistry panel monitoring of CLL in surveillance for several reasons. Often, patients with CLL can show up with new anemia; in such cases, the differential diagnosis is autoimmune hemolytic anemia versus disease progression. An elevated, new LDH level ...

Do you see a role for omidubicel upfront in severe aplastic anemia for patients without a matched donor?

1 Answers

Mednet MemberInvited Expert
Hematology · Dana-Farber Cancer Institute

We typically use cord blood products if there is no available family member donor or reasonably matched unrelated donor. The use of haploidentical family donors is very effective, less expensive, and allows supplementation with CD34+ stem cell boosts if counts are suboptimal DeZern et al., PMID 3234...

How long would you anticoagulate a patient with recurrent VTE who has ongoing risk factors for intracranial bleeding?

1 Answers

Mednet MemberInvited Expert
Hematology · University of Rochester School of Medicine and Dentistry

In general, my preferred agent outside of the inpatient setting in patients with a risk of intracranial bleeding is LMWH. In the inpatient setting, utilizing a bivalirudin or heparin gtt is most appropriate. I would monitor carefully, including potentially imaging 24 hours after the therapeutic anti...

Can AMPLIFY data be extrapolated to use of other BTKi's in combination with venetoclax or would you only ever use acalabrutinib/venetoclax in first line?

1
5 Answers

Mednet Member
Medical Oncology · Roswell Park Cancer Institute

I prefer NOT to extrapolate results, given that BTKis have unique spectra of kinase activities ("kinomes"), different PK/PD properties (such as half life), different adherence rates and dosing schedules, and have different synergistic (especially in a complex immune context that we are committing to...